Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

V Dieras; H Bonnefoi; E Alba; A Awada; B Coudert; X Pivot; J Gligorov; Agnes Jager; S Zambelli; GJ Lindeman; E Charpentier; GT Emmons; I Garcia-Ribas; R Paridaens; Jaap Verweij

doi:10.1007/s10549-019-05305-w

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

V Dieras, H Bonnefoi, E Alba, A Awada, B Coudert, X Pivot, J Gligorov, Agnes Jager, S Zambelli, GJ Lindeman, E Charpentier, GT Emmons, I Garcia-Ribas, R Paridaens, Jaap Verweij

Research output: Contribution to journal › Article › Academic › peer-review

12 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	383-393
Number of pages	11
Journal	Breast Cancer Research and Treatment
Volume	177
Issue number	2
DOIs	https://doi.org/10.1007/s10549-019-05305-w
Publication status	Published - 2019

Research programs

EMC MM-03-86-01

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s10549-019-05305-w

http://hdl.handle.net/1765/118954

Cite this

Dieras, V., Bonnefoi, H., Alba, E., Awada, A., Coudert, B., Pivot, X., Gligorov, J., Jager, A., Zambelli, S., Lindeman, GJ., Charpentier, E., Emmons, GT., Garcia-Ribas, I., Paridaens, R., & Verweij, J. (2019). Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. Breast Cancer Research and Treatment, 177(2), 383-393. https://doi.org/10.1007/s10549-019-05305-w

@article{e92ac540ce8e4117b268ad3795da5b94,

title = "Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics",

author = "V Dieras and H Bonnefoi and E Alba and A Awada and B Coudert and X Pivot and J Gligorov and Agnes Jager and S Zambelli and GJ Lindeman and E Charpentier and GT Emmons and I Garcia-Ribas and R Paridaens and Jaap Verweij",

year = "2019",

doi = "10.1007/s10549-019-05305-w",

language = "Undefined/Unknown",

volume = "177",

pages = "383--393",

journal = "Breast Cancer Research and Treatment",

issn = "0167-6806",

publisher = "Springer",

number = "2",

}

Dieras, V, Bonnefoi, H, Alba, E, Awada, A, Coudert, B, Pivot, X, Gligorov, J, Jager, A, Zambelli, S, Lindeman, GJ, Charpentier, E, Emmons, GT, Garcia-Ribas, I, Paridaens, R & Verweij, J 2019, 'Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics', Breast Cancer Research and Treatment, vol. 177, no. 2, pp. 383-393. https://doi.org/10.1007/s10549-019-05305-w

Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics. / Dieras, V; Bonnefoi, H; Alba, E et al.
In: Breast Cancer Research and Treatment, Vol. 177, No. 2, 2019, p. 383-393.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Iniparib administered weekly or twice-weekly in combination with gemcitabine/carboplatin in patients with metastatic triple-negative breast cancer: a phase II randomized open-label study with pharmacokinetics

AU - Dieras, V

AU - Bonnefoi, H

AU - Alba, E

AU - Awada, A

AU - Coudert, B

AU - Pivot, X

AU - Gligorov, J

AU - Jager, Agnes

AU - Zambelli, S

AU - Lindeman, GJ

AU - Charpentier, E

AU - Emmons, GT

AU - Garcia-Ribas, I

AU - Paridaens, R

AU - Verweij, Jaap

PY - 2019

Y1 - 2019

U2 - 10.1007/s10549-019-05305-w

DO - 10.1007/s10549-019-05305-w

M3 - Article

C2 - 31172407

SN - 0167-6806

VL - 177

SP - 383

EP - 393

JO - Breast Cancer Research and Treatment

JF - Breast Cancer Research and Treatment

IS - 2

ER -